Belgium’s first proton therapy center selects RayStation
Belgium’s first proton therapy center has selected the RayStation® treatment planning system. The facility will be equipped with ProteusOne, IBA’s compact single-room proton therapy solution, and is expected to open in 2018. The new center is a joint project involving Universitaire Ziekenhuizen Leuven (UZ Leuven), Université Catholique de Louvain (UCL), Katholieke Universiteit Leuven (KU Leuven), Cliniques universitaires Saint-Luc and several other Belgian university hospitals.
RayStation will be the main treatment planning system for proton therapy at UZ Leuven and UCL Saint-Luc, and the system will be in clinical use for proton therapy by 2018.
Prof. Dr. Karin Haustermans, head of the department of radiation therapy oncology at UZ Leuven, says: “This unique partnership between leading hospitals and universities brings the benefits of proton therapy to Belgium and puts us on the map as a pioneer of advanced techniques. RayStation is key to getting the most from our equipment and achieving our goal of efficient, patient-centered treatment for all cancer patients.”
Johan Löf, CEO of RaySearch, says: “The choice of ProteusOne together with RayStation creates a perfect match due to the strategic partnership between IBA and RaySearch. This powerful combination will enable highly efficient workflows at the proton therapy center of UZ Leuven and UCL Saint-Luc, with the flexibility to support a diverse range of advanced treatment techniques and machines. We share the partners’ vision of unified, personalized patient care, and we are proud to be part of this pioneering collaboration.”
About proton therapy
Proton therapy is a cutting-edge radiation therapy technique that is growing in popularity worldwide. Its benefits include the ability to deliver maximum dose at a very precise depth in the body, with significantly less irradiation of healthy tissue.
About UZ Leuven
Universitaire Ziekenhuizen (UZ Leuven) is the largest academic hospital in Belgium, with 1,995 beds and more than 9,000 employees. UZ Leuven combines top quality patient care, excellent innovative scientific research and high-standing academic training. It was also the first Belgian hospital to acquire the international JCI label for safe and quality care. More information can be found at: www.uzleuven.be
About UCL Saint-Luc
UCL Saint-Luc is a partnership between Cliniques universitaires Saint-Luc, the largest hospital in Brussels, and Université Catholique de Louvain (UCL). The partnership is focused on research, innovation and teaching.
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon-ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
RaySearch Laboratories AB (publ) is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®, which comprises a new product area for RaySearch, and which will be launched in 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on NASDAQ Stockholm since November 2003.
More information about RaySearch is available at www.raysearchlabs.com
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00